Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for APOB drug discovery. The table below outlines available components and synergistic targets.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | APOB-100 Recombinant Protein (Fragment 3000-4000aa) / Full-length Domains High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 Expressed. |
View APOB Products |
| Gene Delivery | APOB Lentivirus Premade Particles (Full-length ORF) for stable hepatocyte cell lines. Puromycin selectable. | View APOB Products |
| Benchmark Ab | Anti-APOB Recombinant Monoclonal for assay calibration. | View APOB Products |
| Validator | APOB siRNA Set (3 unique sequences) for knockdown verification in HepG2 cells. | View APOB Products |
| Related Target: PCSK9 | PCSK9 Protein & Antibody – synergistic LDL-lowering pathway, critical for combination studies. | View PCSK9 Products |
| Related Target: LDLR | LDLR Extracellular Domain – receptor binding studies for APOB-LDL complex internalization. | View LDLR Products |
| Related Target: ANGPTL3 | ANGPTL3 Protein & Antibody – complementary lipid metabolism target for refractory hypercholesterolemia. | View ANGPTL3 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | TarMart Solution (Technical Spec) |
|---|---|
| Large protein conformational integrity (APOB-100 is 550 kDa) | Fragment-specific domains (B100/B48) with verified disulfide bonding; Native folding confirmed by conformational ELISA. |
| Lipid-binding interference in screening | Lipid-free protein format available; Defined buffer exchange protocols provided. |
| Cross-species translation (Mouse ↔ Human ↔ NHP) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Cross-species epitope mapping panels. |
| Off-target hepatotoxicity screening | Validated siRNA included for specificity controls; ASO-resistant mutant proteins for mechanism validation. |
| Lack of robust positive controls | Clinical Benchmark Antibodies included for precise assay calibration (Western, ELISA, SPR). |
| False positives in secretion assays | Validated sequence-targeted siRNA for absolute knockdown verification. |
Live APOB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (siRNA focus)
- ➤ View All APOB Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for APOB therapeutics is intensifying. Following the clinical validation of first-generation antisense oligonucleotides (ASOs) like mipomersen—which showed efficacy but was limited by hepatic steatosis—the field has shifted to next-generation modalities. RNAi approaches (e.g., inclisiran, lepodisiran) have demonstrated long-lasting LDL reduction via GalNAc-conjugated siRNA, while CRISPR gene editing (pursued by Verve Therapeutics) and targeted protein degradation (LYTACs) are emerging as potentially transformative strategies. Future R&D is directed at oral delivery systems, combination regimens with PCSK9 or ANGPTL3 inhibitors to balance liver lipid profiles, and therapeutic vaccines aiming to induce endogenous antibodies. The convergence of these modalities promises to address a broad spectrum of indications from severe familial hypercholesterolemia to high-risk atherosclerotic cardiovascular disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA (GalNAc-conjugated) | Alnylam, Novartis, Arrowhead | Atherosclerotic CVD, HeFH, HoFH | Liver uptake quantification (need stable APOB-expressing hepatocyte lines via Lentivirus) |
| ASO | Ionis, Novo Nordisk | HoFH, Severe hypercholesterolemia | Nuclease stability assays (need mutant APOB for resistance mechanism studies) |
| Oral Small Molecule | Merck, Lilly | Hyperlipidemia | Binding site mapping (need purified domain fragments) |
| Combination (APOB+PCSK9) | Amgen, Sanofi | High-risk CVD | Dual-target binding assays (need both APOB and PCSK9 proteins) |
| Gene Editing (CRISPR) | Verve Therapeutics | Familial Hypercholesterolemia | Expression reduction assays (need Benchmark Anti-APOB Abs for Western/ELISA) |
| Targeted Degraders (LYTACs) | Emerging Biotechs | Refractory Hypercholesterolemia | Internalization & Degradation Assay (need high-purity recombinant APOB fragments) |
| Therapeutic Vaccines | Vaxxinity | Cardiovascular Disease prevention | Epitope mapping and binding assays (need Human/Cyno cross-reactive antigens) |
TarMart Advantage: Domain-Focused Reagent Design
APOB's massive size (~550 kDa) and hydrophobicity make full-length expression challenging. TarMart uses rationally designed fragments (e.g., N-terminal MTP-binding domain, C-terminal LDLR-binding domain, lipid-binding modules) expressed in HEK293 cells with native glycosylation. All proteins are sequence verified and tested for conformational integrity. Our lentiviral premade particles enable rapid generation of stable cell lines for high-throughput screening, while validated siRNA sets and benchmark antibodies ensure robust assay controls. Cross-species orthologs (human, mouse, cynomolgus) facilitate translational studies.